Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Nihonbashi Life Science HUB

Jan 31, 2020 9:30 AM - Jan 31, 2020 8:00 PM

8F, 1-5-5 Nihonbashi-muromachi, Chuo-ku, Tokyo, 103-0022 Japan

DIA Global Oncology Development 2020


Online Registration has been closed. Onsite Registration will be available at Nihonbashi Life Science HUB.

This program will be conducted in Japanese Language only.

Click Here to View the program in Japanese


The world surrounding cancer treatment continues to evolve rapidly. New, emerging products include not only immuno-oncology drugs, but also regenerative medicine and medical devices, that expand the therapeutic choice in the field of cancer treatment. There are plenty of new topics, such as the remarkable progress of genome analysis technology toward truly personalized medicine, new regulatory frameworks of accelerated approval and Sakigake designation, proposals of innovative clinical trial designs that enable evidence building for rare cancers, better utilization of real world data, and many more. Thanks to the rapidly evlolving digital applications, artificial intelligence (AI), and the Internet of Things (IoT) that affect clinical trial operations, clinical development faces both challenge and opportunity to keep the evaluation of  novel therapeutic products simple and reliable. In addition, as clinical trials are increasingly recognized as a part of “Patients’s Journey”, the demand for improvement of access to the cancer clinical trials has become stronger.


What are we supposed to do in the face of such tide of rapid change in this field? What can we do for the patients in the world who are facing and battling cancer daily? There are growing number of people who disclose that they are cancer patients and influence the public’s image, knowledge and expectations of cancer and its treatment by sharing their story of daily struggles and experiences. Clearly, there is a need for a new stage of discussion on various aspects of potential progress in cancer treatment from a new perspective, free from biased views based on our past successes.


This conference provides a great opportunity to share the latest information about changes in the clinical trial environment (including new trial designs), integration of information technology (IT) into medical care, new development strategies, and to explore the future of cancer treatment. Thank you for your participation.


Want to learn more about DIA Global Oncology Development 2020? You've come to the right site!


Program Committee

  • Toshihiko  Doi, MD, PhD
    Toshihiko Doi, MD, PhD Deputy Director / Chief, Experimental Therapeutics
    National Cancer Center Hospital East, Japan
  • Noboru  Yamamoto, MD, PhD
    Noboru Yamamoto, MD, PhD Deputy Director, Department of Experimental Therapeutics
    National Cancer Center Hospital, Japan
  • Masakazu  Hirata, MD, PhD
    Masakazu Hirata, MD, PhD Clinical Reviewer, Division of RS Consultation, Kansai Branch
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Toshiko  Ishibashi, PhD, RN
    Toshiko Ishibashi, PhD, RN Oncology Medical Science Department, Medical Affairs Division
    Daiichi Sankyo Co., Ltd., Japan
  • Eri  Sekine
    Eri Sekine Executive Vice President
    CMIC Co., Ltd., Japan
  • Takuya  Suzuki
    Takuya Suzuki Associate Director, Japan anad Asia Clinical Development Department
    Eisai Co., Ltd., Japan
  • Tomoko  Takami
    Tomoko Takami Director, Oncology Clinical Development, Oncology Science Unit
    MSD K.K., Japan
  • Atsushi  Tsukamoto, PhD, MSc
    Atsushi Tsukamoto, PhD, MSc Corporate Officer, Head is Therapeutic Area Strategies
    Daiichi Sankyo, United States
  • Hironobu  Saito, PhD
    Hironobu Saito, PhD Corporate Advisor
    Daiichi Sankyo Co., Ltd., Japan
  • Junko  Sato, PhD
    Junko Sato, PhD Associate Executive Director
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Digital Learning Catalog

DIA Learning: eLearning Soultions

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.